Harbin Pharmaceutical Group Co., Ltd. Class A

Harbin Pharmaceutical Group Co., Ltd. Class A

SSSE:600664
4.85
CNY
-0.16
(-3.19%)
0.26EPS
29.92P/E
18.64BMarket Cap
Apr 14Next Earn

Total Valuation

CNY

As of September 30, 2026, Harbin Pharmaceutical Group Co., Ltd. Class A carries a market capitalization of 18.64B, placing it among publicly traded companies globally. Its enterprise value stands at 17.23B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap18.64B
Enterprise Value17.23B

Important Dates

Harbin Pharmaceutical Group Co., Ltd. Class A's next confirmed earnings release is scheduled for April 14, 2027.

Earnings Date4/14/2027

Share Statistics

As of September 30, 2026, Harbin Pharmaceutical Group Co., Ltd. Class A has 2.52B shares outstanding.

Shares Outstanding2.52B

Valuation Ratios

As of September 30, 2026, Harbin Pharmaceutical Group Co., Ltd. Class A trades at a trailing price-to-earnings ratio of 29.92. The price-to-sales ratio is 1.16, and the price-to-book ratio stands at 2.96.

PE Ratio29.92
PS Ratio1.16
PB Ratio2.96
P/TBV Ratio3.23

Enterprise Valuation

As of September 30, 2026, Harbin Pharmaceutical Group Co., Ltd. Class A trades at an EV/EBITDA multiple of 19.46 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.06 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 19.46 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 17.23B versus a market cap of 18.64B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales1.06
EV / EBITDA19.46
EV / EBIT19.46

Financial Position

As of September 30, 2026, Harbin Pharmaceutical Group Co., Ltd. Class A maintains a current ratio of 1.53, meaning it holds 1.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 14.98, indicating elevated leverage, while an interest coverage ratio of 23.68 demonstrates strong ability to service its debt obligations.

Current Ratio1.53
Quick Ratio0.44
Debt / Equity14.98
Debt / EBITDA1.20
Interest Coverage23.68

Financial Efficiency

CNY

These figures cover the twelve months ended September 30, 2026. The company generates approximately 1.62M in revenue per employee across its workforce of 10,039.00, a quick read on workforce productivity versus industry peers.

Revenue Per Employee1.62M
Employee Count10,039.00

Taxes

CNY

Over the twelve months ended September 30, 2026, Harbin Pharmaceutical Group Co., Ltd. Class A recorded 197.07M in income tax expense. That works out to an effective tax rate of 22.56, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 873.40M, leaving 633.23M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax197.07M
Effective Tax Rate22.56

Stock Price Statistics

CNY

As of the close on November 17, 2026, Harbin Pharmaceutical Group Co., Ltd. Class A's stock has gained approximately 26.63% over the past 52 weeks. The 50-day moving average sits at 6.69, while the 200-day moving average is 4.91.

52-Week Price Change26.63%
50-Day Moving Average6.69
200-Day Moving Average4.91

Income Statement

CNY

Over the twelve months ended September 30, 2026, Harbin Pharmaceutical Group Co., Ltd. Class A generated 16.30B in revenue and converted that into 633.23M in net income, yielding earnings per share of 0.26. EBITDA reached 885.54M, while operating income came in at 970.06M.

Revenue16.30B
Gross Profit4.26B
Operating Income970.06M
Pretax Income873.40M
Net Income633.23M
EBITDA885.54M
EBIT885.54M
Earnings Per Share (EPS)0.26

Balance Sheet

CNY

As of September 30, 2026, Harbin Pharmaceutical Group Co., Ltd. Class A holds 3.27B in cash and equivalents against 1.06B in total debt, resulting in a net debt position of -2.38B. Total book value stands at 6.30B, with working capital of 3.93B providing operational flexibility.

Cash & Cash Equivalents3.27B
Total Debt1.06B
Net Debt-2.38B
Equity (Book Value)6.30B
Book Value Per Share2.50
Working Capital3.93B

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-175.91M

Margins

Over the twelve months ended September 30, 2026, Harbin Pharmaceutical Group Co., Ltd. Class A posted a gross margin of 26.13, reflecting its pricing power and cost economics. The operating margin of 5.95 and net profit margin of 3.89 provide insight into operational efficiency.

Gross Margin26.13
Operating Margin5.95
Pretax Margin5.36
Profit Margin3.89
EBITDA Margin5.43

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, Harbin Pharmaceutical Group Co., Ltd. Class A paid dividends of 0.01 per share. The dividend payout ratio of 3.90 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 1.50, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Harbin Pharmaceutical Group Co., Ltd. Class A shareholders.

Dividend Per Share0.01
Payout Ratio3.90
Shareholder Yield1.50

Stock Splits

Harbin Pharmaceutical Group Co., Ltd. Class A's most recent stock split took place on April 6, 2016 with a 10:13 split ratio.

Last Split Date4/6/2016
Split Ratio10:13

Scores

As of September 30, 2026, Harbin Pharmaceutical Group Co., Ltd. Class A has an Altman Z-Score of 3.47, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score3.47